3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
2
CNS
1
Conditions
Glioma
5
Glioblastoma
2
Brain Neoplasms
2
Stomach Neoplasms
1
Sarcoma, Synovial
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Recurrence
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Osteosarcoma
1
Neuroblastoma
1
Neoplasms
1
Multiple Myeloma
1
Mesothelioma
1
Meningeal Carcinomatosis
1
Melanoma
1
Lymphoma, Follicular
1
Lymphoma
1
Lung Neoplasms
1
Leukemia, Myeloid
1
Gliosarcoma
1
Esophageal Neoplasms
1
Colorectal Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Burkitt Lymphoma
1
Breast Neoplasms
1
Astrocytoma
1
Interventions
Temozolomide
8
Irinotecan
7
Melphalan
6
Cyclophosphamide
6
X-Rays
5
Topotecan
5
Phantoms, Imaging
5
Magnetic Resonance Spectroscopy
5
Granulocyte Colony-Stimulating Factor
5
Specimen Handling
4
Nuclear Medicine Department, Hospital
4
Busulfan
4
palbociclib
3
fludarabine
3
Vincristine
3
Thiotepa
3
Stem Cell Transplantation
3
Sirolimus
3
Nivolumab
3
Etoposide
3
Bone Marrow Transplantation
3
Biopsy
3
ulixertinib
2
tipifarnib
2
thymoglobulin
2
tazemetostat
2
selpercatinib
2
omburtamab I-131
2
olaparib
2
larotrectinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Rhabdomyosarcoma
×
Immunotherapy, Adoptive
×
CNS
×
Clear all
NCT02100891
2025-03-19
STIR
Medical College of Wisconsin
Phase 2
Terminated
15 enrolled
11 charts